Poland – Refuse disposal and treatment – ZAGOSPODAROWANIE ODPADÓW O KODACH: 200301 200307 191212 200201 170107 200139 200199 160103 170101 170904 ORAZ ODBIÓR I ZAGOSPODAROWANIE ODPADÓW: 191208 200128 200127* 200111 200110 200132 200121*.

Poland – Refuse and waste related services – ZAGOSPODAROWANIE w okresie od 01.01.2027r. do 31.12.2027r. SELEKTYWNIE ZBIERANYCH ODPADÓW KOMUNALNYCH WIELKOGABARYTOWYCH O KODZIE 20 03 07

Poland – Refuse and waste related services – Zagospodarowanie odpadów komunalnych pochodzących z terenu gminy Borek Wlkp. w instalacji przetwarzania odpadów komunalnych.

Poland – Refuse and waste related services – Przetarg nieograniczony

Poland – Snow-clearing services – Zimowe utrzymanie dróg gminnych i powiatowych w sezonie zimowym 2026/2027, na terenie miasta Wisły

Poland – Refuse and waste related services – Odbieranie i zagospodarowanie odpadów komunalnych od właścicieli nieruchomości, na których zamieszkują mieszkańcy w Gminie Pionki 01.01.2027 do 31.12.2028

Poland – Refuse collection services – Odbiór i zagospodarowanie odpadów komunalnych z terenu Gminy Karczew – trzy Części

Expected Outcome: This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as: The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scaling The absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes: By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a firmware stack (scheduler, controller, compiler), validated via hardware-agnostic benchmarks and hybrid photonic-HPC applications demonstrating classical-quantum crossover By 2030, delivery of a full-stack, high-connectivity photonic quantum computer, with modular scalability, integrated…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…

Expected Outcome: This flagship pilot is the culmination of the entire activity catalogue carried out by the CCAM Partnership since its launch in 2021. It will combine in one project the most promising CCAM use-cases across three key domains, with the technological advancements from all its R&I clusters [1] supporting and enabling CCAM systems and services towards market uptake. This action is expected to contribute to all the following outcomes: Large-scale demonstrations of inclusive, user-oriented, and well-integrated CCAM systems and services for people and goods in mixed traffic through Field Operational Tests (FOTs), Technology Pilots, and Living Labs, building upon advanced and emerging SAE Level 2 systems to move towards SAE Level 3 and 4 functionalities, at multiple test sites and corridors showcasing CCAM potential [2] , for a minimum of 12 months. Validation of enabling technologies that facilitate the extension of Operational Design Domains (ODDs) in large-scale operations and enhance perception performance under poor lighting and adverse weather conditions in large-scale demonstrations and pilots. Assessment of deployment readiness and demonstration of technological…